Parmodulin 2 (ML161),a probe, is an allosteric inhibitor of protease-activated receptor 1 (PAR1) with an IC50 of 0.26 μM. Parmodulin 2 inhibits platelet aggregation induced by a PAR1 peptide agonist or by thrombin and has shown cytoprotective effects[1, 2].
Parameter
Value
Chemical Name
2-Bromo-N-(3-butyramidophenyl)benzamide
CAS No.
423735-93-7
Synonyms
2-Bromo-N-(3-butyramidophenyl)benzamide;ML 161;2-bromo-N-[3-(butanoylamino)phenyl]benzamide;ML-161;2-Bromo-N-[3-[(1-oxobutyl)amino]phenyl]-benzamide;ML161;2-Bromo-N-[3-[(1-oxobutyl)amino]phenyl]benzamide;2-bromo-N-[3-(butyrylamino)phenyl]benzamide;AK142591;SMR000193713;MLS000571703;Cambridge id 5946339;Oprea1_852187;MLS002699906;ARONIS27179;AOB1565;DFOVLSMXPWPCFH-UHFFFAOYSA-N;HMS3651N10;BENZAMIDE, 2-BROMO-N-[3-[(1-OXOBUTYL)AMINO]PHENYL]-;HMS2461M06;BC;Parmodulin 2;2-bromo-N-[3-(1-oxobutylamino)phenyl]benzamide;BENZAMIDE, 2-BROMO-N-[3-[
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological Activity
Parmodulin 2 (ML161),a probe, is an allosteric inhibitor of protease-activated receptor 1 (PAR1) with an IC50 of 0.26 μM. Parmodulin 2 inhibits platelet aggregation induced by a PAR1 peptide agonist or by thrombin and has shown cytoprotective effects[1, 2].
In Vitro
No in vitro data are provided in the current product source. Contact us for further information.
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
Adavivint is a potent and selective inhibitor of canonical Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells.
WZ4002 is a mutant selective EGFR inhibitor with IC50s of 2, 8, 3 and 2 nM for EGFRL858R, EGFRL858R/T790M, EGFRE746_A750 and EGFRE746_A750/T790M, respectively.
GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.
Fluzoparib (SHR-3162) is a novel, potent and orally available inhibitor of PARP; potently inhibited PARP1 enzyme activity and induced DNA double-strand breaks, G2/M arrest and apoptosis in homologous recombination…
